熱門資訊> 正文
Nektar Therapeutics继续飙升，股价再上涨25%
2025-06-26 02:14
- 內克塔治療(NKTR) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Nektar Therapeutics (NASDAQ:NKTR), which closed Tuesday up ~156% after its lead asset, rezpegaldesleukin, met its main goal in a mid-stage trial for atopic dermatitis, also known as eczema, is up another 25% in Wednesday afternoon trading.
- "We believe that the REZOLVE-AD study results clearly demonstrate that Nektar has established a new biology and harnessed the promise of (regulatory T cell proliferators) as an important potential therapeutic modality to treat inflammatory skin disorders and other autoimmune conditions," Nektar CEO Howard Robin said in a statement.
- Results showed that between 34% and 46% of patients had at least a 75% improvement in eczema symptoms.
- The company plans to release data from the long-term maintenance section of REZOLVE-AD in Q1 2026.
More on Nektar Therapeutics
- Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC
- Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
- Nektar surges as lead asset succeeds in mid-stage trial for eczema
- Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
- Seeking Alpha’s Quant Rating on Nektar Therapeutics
推薦文章
7月關税收入達創紀錄的277億美元，特朗普稱這對「我們國家來説不可思議」
一圖看懂 | 騰訊Q2營收、淨利齊超預期！AI投入效益加速顯現，毛利率提升至57%
特朗普家族加密貨幣財富暴增：與PancakeSwap合作發行USD1，家族持幣市值約45億美元
騰訊打頭陣，科網股中報季來襲！業績分化成市場焦點？
華盛早報丨退市！中國恆大16年上市之路終結；「穩定幣第一股」Circle宣佈股票發行
AI競賽太燒錢！CoreWeave(CRWV.US)Q2虧損激增，Q3指引令人失望
量子計算龍頭Rigetti Computing(RGTI.US)Q2營收不及預期 推出多芯片量子計算機
8月13日外盤頭條：特朗普考慮起訴鮑威爾 抨擊高盛對關税判斷 美國務卿與俄外長通話 木頭姐大舉買入Block
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
